175 related articles for article (PubMed ID: 22169985)
1. Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.
Cho HJ; Chong S; Chung SJ; Shim CK; Kim DD
Pharm Res; 2012 Apr; 29(4):1007-19. PubMed ID: 22169985
[TBL] [Abstract][Full Text] [Related]
2. Design of a multicomponent peptide-woven nanocomplex for delivery of siRNA.
Jun E; Kim S; Kim JH; Cha K; So IS; Son HN; Lee BH; Kim K; Kwon IC; Kim SY; Kim IS
PLoS One; 2015; 10(2):e0118310. PubMed ID: 25705892
[TBL] [Abstract][Full Text] [Related]
3. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
[TBL] [Abstract][Full Text] [Related]
4. Chitosan-based hybrid nanocomplex for siRNA delivery and its application for cancer therapy.
Ki MH; Kim JE; Lee YN; Noh SM; An SW; Cho HJ; Kim DD
Pharm Res; 2014 Dec; 31(12):3323-34. PubMed ID: 24858398
[TBL] [Abstract][Full Text] [Related]
5. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
6. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
7. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
Liu CW; Lin WJ
J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
[TBL] [Abstract][Full Text] [Related]
8. Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles.
Liu Y; Song Z; Zheng N; Nagasaka K; Yin L; Cheng J
Nanoscale; 2018 Aug; 10(32):15339-15349. PubMed ID: 30070662
[TBL] [Abstract][Full Text] [Related]
9. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Wen Z; Feng Y; Hu Y; Lian L; Huang H; Guo L; Chen S; Yang Q; Zhang M; Wan L; Xu K; Degejirifu ; Yan X
Aging (Albany NY); 2021 Jan; 13(2):1872-1882. PubMed ID: 33440348
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer.
Chen WH; Lecaros RL; Tseng YC; Huang L; Hsu YC
Cancer Lett; 2015 Apr; 359(1):65-74. PubMed ID: 25596376
[TBL] [Abstract][Full Text] [Related]
11. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
12. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
[TBL] [Abstract][Full Text] [Related]
13. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system.
Beale G; Hollins AJ; Benboubetra M; Sohail M; Fox SP; Benter I; Akhtar S
J Drug Target; 2003 Aug; 11(7):449-56. PubMed ID: 15203934
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-modified redox-sensitive hybrid nanocomplex loading with siRNA for non-small-cell lung carcinoma therapy.
Chen D; Zhang P; Li M; Li C; Lu X; Sun Y; Sun K
Drug Deliv; 2022 Dec; 29(1):574-587. PubMed ID: 35156491
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.
Kim JS; Kim MW; Kang SJ; Jeong HY; Park SI; Lee YK; Kim HS; Kim KS; Park YS
Int J Nanomedicine; 2018; 13():4817-4830. PubMed ID: 30214190
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891.
Uehara N; Otsuki N; Kubo M; Kitamoto J; Kojima Y; Teshima M; Shinomiya H; Shirakawa T; Nibu KI
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1231. PubMed ID: 32671980
[TBL] [Abstract][Full Text] [Related]
17. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
18. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
19. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
20. Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells.
Nguyen PV; Hervé-Aubert K; David S; Lautram N; Passirani C; Chourpa I; Aubrey N; Allard-Vannier E
Eur J Pharm Biopharm; 2020 Dec; 157():74-84. PubMed ID: 33059006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
